Home › Burkitt Lymphoma › Minnesota › Rochester
Burkitt Lymphoma clinical trials in Rochester, MN
4 studies for Burkitt Lymphoma are looking for participants at sites in and around Rochester (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPhase 2
- Mayo Clinic in Rochester, Rochester
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
RecruitingPhase 3
- Mayo Clinic in Rochester, Rochester
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RecruitingPhase 3
- Mayo Clinic in Rochester, Rochester
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RecruitingPhase 1/2
- Mayo Clinic, Clinical Trials Referral Office, Rochester
Burkitt Lymphoma trials in other cities
- Houston, TX21 studies
- Milwaukee, WI16 studies
- Philadelphia, PA16 studies
- New York City, NY14 studies
- Chicago, IL14 studies
- Cincinnati, OH12 studies
- Atlanta, GA12 studies
- Seattle, WA11 studies
- Durham, NC10 studies
- Boston, MA10 studies
- Kansas City, MO10 studies
- Aurora, CO10 studies
Other studies in Rochester
- Breast Cancer42 studies
- Non-Small Cell Lung Cancer37 studies
- Metastatic Cancer31 studies
- Cancer (all types)30 studies
- Colorectal Cancer29 studies
- Ovarian Cancer29 studies
- Multiple Myeloma24 studies
- Prostate Cancer22 studies
- Heart Failure22 studies
- Pancreatic Cancer22 studies
- Lung Cancer20 studies
- Endometrial Cancer20 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.